Gastroesophageal reflux disease: Difference between revisions
| Line 21: | Line 21: | ||
==Treatment== | ==Treatment== | ||
===Other treatments=== | ===Other treatments=== | ||
Revision as of 23:03, 30 August 2012
| Gastroesophageal reflux disease | |
| ICD-10 | K21 |
|---|---|
| ICD-9 | 530.81 |
| OMIM | 109350 |
| DiseasesDB | 23596 |
| MeSH | D005764 |
|
Gastroesophageal reflux disease Microchapters |
|
Differentiating Gastroesophageal Reflux Disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Gastroesophageal reflux disease On the Web |
|
American Roentgen Ray Society Images of Gastroesophageal reflux disease |
|
Directions to Hospitals Treating Gastroesophageal reflux disease |
|
Risk calculators and risk factors for Gastroesophageal reflux disease |
For patient information click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: GERD, GORD, gastroesophageal reflux, oesophageal reflux, peptic esophagitis, esophageal reflux
Treatment
Other treatments
In 2000 , the U.S. Food and Drug Administration (FDA) approved two endoscopic devices to treat chronic heartburn. One system, Endocinch, puts stitches in the LES to create little pleats that help strengthen the muscle. Another, the Stretta Procedure, uses electrodes to apply radio frequency energy to the LES. The long term outcomes of both procedures compared to a Nissen fundoplication are still being determined.
Subsequently the NDO Surgical Plicator was FDA cleared for the endoscopic GERD treatment. The Plicator creates a plication, or fold, of tissue near the gastroesophageal junction, and fixates the plication with a suture-based implant. The Plicator is currently marketed by NDO Surgical, Inc. [2].
Another treatment that involved injection of a solution during endoscopy into the lower esophageal wall was available for about one year ending in late 2005. It was marketed under the name Enteryx. It was removed from the market due to several reports of complications from misplaced injections.
Barrett's esophagus
Barrett's esophagus, a type of dysplasia, is a precursor high-grade dysplasia, which is in turn a precursor condition for carcinoma. The risk of progression from Barrett's to dysplasia is uncertain but is estimated to include 0.1% to 0.5% of cases, and has probably been exaggerated in the past. Due to the risk of chronic heartburn progressing to Barrett's, EGD every 5 years is recommended for patients with chronic heartburn, or who take drugs for chronic GERD.
References
External links
- GERD patient information page at NIH
- KidsHealth GERD Information for Kids
- Mayo Clinic review of diagnosis and treatment options
- Overview at Cleveland Clinic
de:Refluxösophagitis it:Malattia da reflusso gastroesofageo no:Gastroøsofageal refluks sv:Gastroesofageal refluxsjukdom